Which is better: patents on the fundamental science for creating a new class of drugs--or the know-how for making drugs based on the idea? In one of the few bright areas of discovery-based biotech, RNA interference (RNAi), the battle between the two philosophical positions has been joined as an investor group has beaten Alnylam, the IP leader in RNAi, to the control of Ribozyme Pharmaceutical's RNA chemistry know-how.
Which is better: patents on the fundamental science for creating a new class of drugs--or the know-how for making drugs based on the idea?
In one of the few bright areas of discovery-based biotech, RNA interference (RNAi), the battle between the two philosophical positions has been joined. (See RNAi Revs Up, Start-Up, October 2002...
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The UK major's asthma drug gets a key expanded approval.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.
The French drugmaker is expanding its neurology activities with the $470m deal.
